06/22/2026 | Press release | Distributed by Public on 06/22/2026 05:05
EyePoint, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders on June 18, 2026 via live webcast (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders, upon the recommendation of the Company's Board of Directors (the "Board"), approved an amendment (the "Plan Amendment") to the EyePoint, Inc. 2023 Long-Term Incentive Plan (as amended, the "2023 Plan") to increase the number of shares of common stock of the Company ("Common Stock") authorized for issuance thereunder by 4,900,000 shares.
A summary of the Plan Amendment is set forth in the Company's 2026 Annual Meeting Proxy Statement filed with the Securities and Exchange Commission on April 27, 2026 (the "Proxy Statement"). That summary and the above description of the Plan Amendment do not purport to be complete and are qualified in their entirety by reference to the 2023 Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
On April 21, 2026, the record date for the Annual Meeting, there were 83,795,203 shares of Common Stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 71,010,327 or 84.74%, were present in person via virtual communication or voted by proxy, which constituted a quorum. Each stockholder is entitled to one vote for each share held and cumulative voting for directors is not permitted. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:
The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2027 Annual Meeting of Stockholders and until such person's successor is duly elected and qualified. The voting on this proposal is set forth below:
|
Vote Type |
Vote Results |
|||||
|
Göran Ando, M.D. |
For |
59,796,165 |
||||
|
Withheld |
3,216,592 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
Jay S. Duker, M.D. |
For |
62,424,283 |
||||
|
Withheld |
588,474 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
John B. Landis, Ph.D. |
For |
62,146,666 |
||||
|
Withheld |
866,091 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
Wendy DiCicco |
For |
61,675,612 |
||||
|
Withheld |
1,337,145 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
Karen Zaderej |
For |
62,154,600 |
||||
|
Withheld |
858,157 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
Stuart Duty |
For |
62,317,098 |
||||
|
Withheld |
695,659 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
Fred Hassan |
For |
61,862,078 |
||||
|
Withheld |
1,150,679 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
|
Reginald J. Sanders, M.D. |
For |
62,327,522 |
||||
|
Withheld |
685,235 |
|||||
|
Broker Non-Votes |
7,997,570 |
|||||
The Company's stockholders approved the 2023 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 4,900,000 shares. The voting on this proposal is set forth below:
|
Vote type |
Vote Results |
|||
|
For |
49,662,176 |
|||
|
Against |
13,010,393 |
|||
|
Abstain |
340,188 |
|||
|
Non Votes |
7,997,570 |
|||
The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The voting on this proposal is set forth below:
|
Vote type |
Vote Results |
|||
|
For |
60,563,563 |
|||
|
Against |
2,033,575 |
|||
|
Abstain |
415,619 |
|||
|
Non Votes |
7,997,570 |
|||
The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting on this proposal is set forth below:
|
Vote type |
Vote Results |
|||
|
For |
70,608,563 |
|||
|
Against |
86,031 |
|||
|
Abstain |
315,733 |
|||
|
Exhibit No. |
Description |
|
|
10.1 |
EyePoint, Inc. Amendment No 3. to 2023 Long-Term Incentive Plan. |
|
|
104 |
Cover Page Interactive Data File (embedded within the inline XBRL document) |